109229
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
重组人脑利钠肽治疗急性心肌梗死患者经皮冠状动脉介入治疗术后对心功能的影响：一项回顾性对照研究
Authors Yu H, Li N, Li J, Zhu J
Received 8 July 2025
Accepted for publication 26 October 2025
Published 4 November 2025 Volume 2025:18 Pages 6651—6659
DOI https://doi.org/10.2147/IJGM.S552471
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Yuriy Sirenko
Hongbo Yu,1 Nannan Li,2 Jie Li,3 Jie Zhu4
1Department of Cardiovascular Medicine II, Qinhuangdao Hospital of Dongfang Hospital, Beijing University of Chinese Medicine (Qinhuangdao Hospital of Traditional Chinese Medicine), Qinhuangdao, Hebei, 066000, People’s Republic of China; 2Department of Cardiology, Dongying District People’s Hospital, Dongying, Shandong, People’s Republic of China; 3Department of Cardiology, The Fifth People’s Hospital of Dongying, Dongying, Shandong, People’s Republic of China; 4Department of Cardiovascular Diseases, Hengshui Hospital of Traditional Chinese Medicine, Hengshui, Hebei, 053000, People’s Republic of China
Correspondence: Jie Zhu, Email i2ed9q@163.com
Objective: To investigate the efficacy of recombinant human brain natriuretic peptide (rhBNP) therapy after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) and its impact on cardiac function.
Methods: In this retrospective controlled study, 104 AMI patients who underwent PCI at our hospital between September 2021 and December 2024 were consecutively enrolled and assigned to groups based on the treatment period. The control group (n=52) (patients admitted from September 2021 to December 2022) received standard guideline-directed medical therapy (GDMT), while the observation group (n=52) (patients admitted from January 2023 to December 2024) received additional intravenous rhBNP treatment for 72 hours on top of GDMT. The therapeutic effects, cardiac ultrasound parameters (LVEF, LVEDD, LVESD, FS), key myocardial injury markers (CK-MB, cTnI), inflammatory markers (IL-6, TNF-α, Hcy), and major adverse cardiovascular events (MACE) incidence were compared. Multivariate regression analyses were performed to adjust for potential baseline confounders.
Results: The observation group demonstrated a significantly higher overall efficacy than the control group (94.23% vs 78.85%, P< 0.05). Post-treatment, both groups showed significant improvements in LVEF, FS, LVESD, and reductions in CK-MB, cTnI, IL-6, TNF-α, and Hcy, with the observation group exhibiting more pronounced benefits (P< 0.05). The between-group differences remained significant after adjusting for baseline characteristics. The incidence of MACE during the 6-month follow-up was significantly lower in the observation group (5.77% vs 19.23%, P< 0.05).
Conclusion: Adjunctive rhBNP therapy after PCI in AMI patients provides significant clinical benefits, including enhanced improvement of cardiac function, reduced myocardial injury and inflammatory stress, and a lower risk of MACE. However, these findings should be interpreted considering the study’s limitations, including its retrospective design and single-center nature. Future prospective randomized trials are warranted for confirmation.
Keywords: acute myocardial infarction, PCI, recombinant human brain natriuretic peptide, efficacy, cardiac function, MACE
1Department of Cardiovascular Medicine II, Qinhuangdao Hospital of Dongfang Hospital, Beijing University of Chinese Medicine (Qinhuangdao Hospital of Traditional Chinese Medicine), Qinhuangdao, Hebei, 066000, People’s Republic of China; 2Department of Cardiology, Dongying District People’s Hospital, Dongying, Shandong, People’s Republic of China; 3Department of Cardiology, The Fifth People’s Hospital of Dongying, Dongying, Shandong, People’s Republic of China; 4Department of Cardiovascular Diseases, Hengshui Hospital of Traditional Chinese Medicine, Hengshui, Hebei, 053000, People’s Republic of China
Correspondence: Jie Zhu, Email i2ed9q@163.com
Objective: To investigate the efficacy of recombinant human brain natriuretic peptide (rhBNP) therapy after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) and its impact on cardiac function.
Methods: In this retrospective controlled study, 104 AMI patients who underwent PCI at our hospital between September 2021 and December 2024 were consecutively enrolled and assigned to groups based on the treatment period. The control group (n=52) (patients admitted from September 2021 to December 2022) received standard guideline-directed medical therapy (GDMT), while the observation group (n=52) (patients admitted from January 2023 to December 2024) received additional intravenous rhBNP treatment for 72 hours on top of GDMT. The therapeutic effects, cardiac ultrasound parameters (LVEF, LVEDD, LVESD, FS), key myocardial injury markers (CK-MB, cTnI), inflammatory markers (IL-6, TNF-α, Hcy), and major adverse cardiovascular events (MACE) incidence were compared. Multivariate regression analyses were performed to adjust for potential baseline confounders.
Results: The observation group demonstrated a significantly higher overall efficacy than the control group (94.23% vs 78.85%, P< 0.05). Post-treatment, both groups showed significant improvements in LVEF, FS, LVESD, and reductions in CK-MB, cTnI, IL-6, TNF-α, and Hcy, with the observation group exhibiting more pronounced benefits (P< 0.05). The between-group differences remained significant after adjusting for baseline characteristics. The incidence of MACE during the 6-month follow-up was significantly lower in the observation group (5.77% vs 19.23%, P< 0.05).
Conclusion: Adjunctive rhBNP therapy after PCI in AMI patients provides significant clinical benefits, including enhanced improvement of cardiac function, reduced myocardial injury and inflammatory stress, and a lower risk of MACE. However, these findings should be interpreted considering the study’s limitations, including its retrospective design and single-center nature. Future prospective randomized trials are warranted for confirmation.
Keywords: acute myocardial infarction, PCI, recombinant human brain natriuretic peptide, efficacy, cardiac function, MACE